Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer

Authors

Gulden Menderes, Section of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Mitchell Clark, Department of Obstetrics and Gynecology, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT 06610, USA.
Alessandro D. Santin, Section of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.

Document Type

Article

Publication Title

Discovery medicine

Abstract

Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related recurrences and subsequent deaths. With such a dismal prognosis, there is an expanding role for novel targeted approaches in the treatment of USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. The results emphasize the relevance of these novel therapeutic targets for biologic therapy of USC, which will be reviewed in this article.

First Page

293

Last Page

303

Publication Date

4-1-2016

Recommended Citation

Menderes, Gulden; Clark, Mitchell; and Santin, Alessandro D., "Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer" (2016). MIGs. 4.
https://scholar.bridgeporthospital.org/migs/4